LBA65 Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: Interim analysis (IA) of the phase II MDT-BRIDGE study

M. Reck, Nicolas Girard, Ernest Nadal, C.M. Gay, Andrea Riccardo Filippi, L.W. Martin, Cordula Petersen, David A. Cairns, Benoît Roch, Ilaria Attili, Rafael Álvarez, Alexandre Boyer, Margarita Majem, Arelis Robinson, E.L. Buchmeier, Matteo Giaj Levra, Li Li, I. Diaz Perez, N.E. Georgoulia, Jonathan Spicer